Trince

Trince Bio is a private, pre-revenue platform company pioneering a gentler method of cell transfection called photoporation. Its core LumiPoreTM platform uses laser light and proprietary photothermal nanosensitizers to create transient pores in cell membranes, enabling efficient delivery of payloads like gene-editing complexes and proteins while preserving cell health and function. The company is targeting two primary markets: the research tools sector for high-throughput screening and the high-growth cell therapy manufacturing space, where its technology promises to improve yields and reduce production timelines. With early access programs underway and a distributor agreement in place, Trince is transitioning from technology development towards initial commercial engagement.

LumiPoreTM photoporation platform: a laser-based, nanoparticle-mediated system that creates transient pores in cell membranes for efficient, gentle delivery of diverse payloads (nucleic acids, proteins, gene-editing complexes).

Trince competes with established transfection methods like electroporation, viral vectors, and chemical reagents, which have drawbacks in efficiency, toxicity, or cost. It also faces emerging competition from other novel physical delivery platforms (e.g., acoustic, microfluidic). Its differentiation lies in the unique photoporation mechanism promising superior cell viability and payload flexibility.